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Abstract
Introduction Accumulating evidence suggests that fibroblasts
play a pivotal role in promoting the growth of breast cancer cells.
The objective of the present study was to characterize and
validate an in vitro model of the interaction between small
numbers of human breast cancer cells and human fibroblasts.
Methods We measured the clonogenic growth of small
numbers of human breast cancer cells co-cultured in direct
contact with serum-activated, normal human fibroblasts. Using
DNA microarrays, we also characterized the gene expression
profile of the serum-activated fibroblasts. In order to validate the
in vivo relevance of our experiments, we then analyzed clinical
samples of metastatic breast cancer for the presence of
myofibroblasts expressing α-smooth muscle actin.
Results Clonogenic growth of human breast cancer cells
obtained directly from in situ and invasive tumors was
dramatically and consistently enhanced when the tumor cells
were co-cultured in direct contact with serum-activated
fibroblasts. This effect was abolished when the cells were co-
cultured in transwells separated by permeable inserts. The
fibroblasts in our experimental model exhibited a gene
expression signature characteristic of 'serum response' (i.e.
myofibroblasts). Immunostaining of human samples of
metastatic breast cancer tissue confirmed that myofibroblasts
are in direct contact with breast cancer cells.
Conclusion Serum-activated fibroblasts promote the
clonogenic growth of human breast cancer cells in vitro through
a mechanism that involves direct physical contact between the
cells. This model shares many important molecular and
phenotypic similarities with the fibroblasts that are naturally
found in breast cancers.
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Introduction
There is now increasing evidence that stromal cells play a
pivotal role in promoting the growth of most carcinomas,
including breast cancer [1-4]. The myofibroblast is the pre-
dominant type of stromal cell found in most carcinomas
[1,5,6]. Myofibroblasts are defined by their characteristic
expression of α-smooth muscle actin as well as certain
other markers such as vimentin and desmin [1]. Tumor-
associated myofibroblasts are believed to originate from
normal fibroblasts and are similar or identical to the myofi-
broblasts found in healing wounds [1]. They are largely
responsible for the desmoplasia that is characteristically
present in carcinomas because they secrete large amounts
of collagen and other extracellular matrix proteins.
A large body of work has been done to investigate the inter-
actions between fibroblasts and carcinoma cells [1-4,7-9].
Recently, an orthotopic xenograft model was created in
mice in which both the stromal and epithelial components
of the reconstructed mammary gland are of human origin
[10]. This complex model again underscored the critical
role played by heterotypic interactions in human breast car-
cinogenesis. Many other in vitro and in vivo studies have
demonstrated that fibroblasts can promote the growth of
cancer cells [11-16]. We are not aware, however, of any
previous reports of studies investigating the ability of
fibroblasts to promote the clonogenic growth of small num-
bers of primary breast cancer cells in vitro.
To address this issue, we first co-cultured low numbers of
a slow growing human breast cancer cell line (UACC-812)Breast Cancer Research    Vol 7 No 3    Samoszuk et al.
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with a monolayer of normal human fibroblasts derived from
human breast tissue. We selected this tumor cell line for
our initial experiments because it was derived in 1991 from
a ductal carcinoma (stage II, grade IV) and closely mimics
the glandular morphology (Fig. 1a) and slow growth rate
(doubling time > 100 hours) of primary breast cancer [17].
In order to validate the potential clinical relevance of our
experiments, we then co-cultured a monolayer of serum-
activated fibroblasts with tumor cells obtained directly from
human breast cancer samples. Gene expression profiling
by microarrays and immunocytochemistry were used to
characterize the serum-activated fibroblasts. Finally, we
examined 25 randomly selected surgical specimens con-
taining metastatic breast cancer of varying grades for the
presence of fibroblasts expressing α-smooth muscle actin
in close proximity to tumor cells. Here, we report the novel
observation that serum-activated fibroblasts promote the
clonogenic growth of small numbers of breast cancer cells
obtained directly from human tumor samples. Moreover, we
show that fibroblasts activated by serum in vitro share
Figure 1
Microscopic appearance of tumor cells and fibroblasts Microscopic appearance of tumor cells and fibroblasts. (a) Numerous clumps of UACC-812 tumor cells resembling abortive mammary glands are 
evident. (b) UACC-812 breast cancer cells seeded at low density on a monolayer of serum-activated fibroblasts. Note the gland formation and the 
invasive infiltration by tumor cells into fibroblasts. Primary tumor cells derived from (c) human ductal carcinoma in situ and from (d) invasive ductal 
carcinoma co-cultured with fibroblasts yielded clonogenic growth next to myofibroblasts that expressed α-smooth muscle actin (pink immunostain). 
Breast cancer cells grown (e) on a monolayer of B16 cells or (f) without a monolayer of fibroblasts generally grew as individual cells identifiable by 
their red staining for epithelial membrane antigen. (g) Serum-activated fibroblasts also uniformly expressed abundant syndecan-1, as detected by 
immunocytochemical staining.Available online http://breast-cancer-research.com/content/7/3/R274
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many molecular features with the fibroblasts that are natu-
rally and abundantly present within primary human breast
cancers and metastases.
Methods
Breast cancer cell line and fibroblasts
The UACC-812 human breast cancer cell line (American
Type Culture Collection [ATCC], Manassas, VA, USA) was
passaged in Leibovitz's medium supplemented with 15%
fetal calf serum prior to use. Normal fibroblasts (CCD-
1068SK; ATCC) obtained from the breast of a 65-year-old
female were passaged at 37°C in minimal essential
medium (Eagle's) supplemented with 2 mmol/l L-glutamine,
Earle's balanced salt solution (1.5 g/l), sodium bicarbonate,
0.1 mmol/l nonessential amino acids, 1 ml sodium pyruvate,
and 10% fetal calf serum in a 5% carbon dioxide atmos-
phere. All cell culture reagents were obtained from ATCC.
Our co-culture experiments utilized confluent monolayers
of fibroblasts that had been passaged no more than 14
days. This precaution ensured that the fibroblasts were not
senescent or transformed.
Immunocytochemical assays of cultured cells
The presence of α-smooth muscle actin, epithelial mem-
brane antigen (a marker of breast cancer cells), and synde-
can-1 was detected by in situ immunostaining of methanol-
fixed cells using prediluted murine monoclonal antibodies
directed against α-smooth muscle actin, or syndecan-1, or
epithelial membrane antigen (Chemicon International,
Temecula, CA, USA). Bound antibody was then detected
with an alkaline phosphatase procedure (IHC Select® AP/
Fast Red; Chemicon International) in accordance with the
manufacturer's directions.
Clonogenic co-culture assay
We seeded 100 UACC-812 breast cancer cells into indi-
vidual wells of a 96-well cell culture plate containing a con-
fluent monolayer of fibroblasts growing in fibroblast growth
medium supplemented with 10% fetal calf serum. Controls
included co-culture with fibroblasts in serum-free medium,
co-culture with a monolayer of a nonfibroblast cell line
(murine B16 melanoma), and culture in medium with fetal
calf serum but without fibroblasts. In order to determine
whether a soluble factor was responsible for any effect that
we observed, we also co-cultured the fibroblasts and
breast cancer cells separately on opposite sides of perme-
able transwell inserts with a 0.2 µm pore size (Nalge-Nunc
International, Rochester, NY, USA). The inserts permitted
diffusion of any soluble growth factors produced by the
fibroblasts but prevented direct contact between the cells.
All of the experimental and control combinations were per-
formed in triplicate wells of 96-well culture plates.
At intervals of 3–4 days, fresh medium was added. After 14
days the cells were fixed with 70% ethanol for 10 min prior
to staining for 3 min with 0.1% toluidine blue. Using
inverted microscopy, we counted the number of colonies
containing 12 or more tumor cells in each well. A colony
was defined as a cluster of epithelial cells in direct contact
with one another. The means and standard deviations for
each condition were compared statistically using pair-wise
comparisons with the appropriate control in an unpaired,
two-tailed t-test.
Proliferation and apoptosis assays
In order to determine whether serum-activated fibroblasts
promote the growth of breast cancer cells in vitro even at
higher densities of tumor cells, we used flow cytometry to
characterize the apoptotic and proliferative rates of breast
cancer cells co-cultured with fibroblasts. Confluent monol-
ayers of fibroblasts in T-75 culture flasks (Corning Inc.,
Corning, NY, USA) were seeded with 500,000 breast can-
cer cells and co-cultured for 1 week with a medium change
at 4 days. On day 7 we separated the breast cancer cells
from the fibroblasts using magnetic beads conjugated to
epithelial membrane antigen (DYNAL MPC-S Kit; Dynal
AS, Oslo, Norway) in accordance with the manufacturer's
directions. The negative control consisted of 500,000
breast cancer cells cultured in the same medium but with-
out fibroblasts.
The purified breast cancer cells were then analyzed for their
proportions of proliferating and apoptotic cells using the
Absolute-S™ Kit for Measuring Cell Proliferation by Dual
Color Flow Cytometry (Chemicon International) in accord-
ance with the manufacturer's directions. The stained cells
were analyzed on a Coulter®  Epics®-MCL (Coulter,
Hialeah, FL, USA) flow cytometer using appropriate posi-
tive and negative controls.
Co-culture of primary breast cancer cells and fibroblasts
We aseptically dissected small pieces of tissue (2–3 mm in
diameter) from three cases of invasive ductal carcinoma of
the breast, three cases of ductal carcinoma in situ, and
seven specimens of normal breast tissue. The tissue frag-
ments were then mechanically disaggregated using Medi-
cons™ (BD Biosciences, San Jose, CA, USA) with a 50 µm
mesh size. This method routinely yielded between 1000
and 10,000 viable epithelial cells, as determined by trypan
blue staining and expression of epithelial membrane
antigen.
We seeded about 100 epithelial cells into individual wells
of 96-well cell culture plates containing a monolayer of
fibroblasts. The control consisted of epithelial cells seeded
into wells without fibroblasts. At the end of 14 days of co-
culture, the cells were stained in situ with toluidine blue as
described above, and the colonies of tumor cells (defined
as 12 or more adjacent epithelial cells) in each well were
counted using inverted microscopy.Breast Cancer Research    Vol 7 No 3    Samoszuk et al.
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Target preparation/processing for GeneChip analysis
We used gene expression analysis on Affymetrix U133A
cDNA microarrays (Affymetrix Inc., Santa Clara, CA, USA)
to compare the molecular signatures of serum-activated
fibroblasts with those of serum-starved fibroblasts (experi-
ment 1). We also compared the gene expression patterns
of serum-activated fibroblasts cultured alone with those of
serum-activated fibroblasts co-cultured with breast cancer
cells for 3 days before being purified with magnetic beads
(experiment 2). All assays were performed in duplicate at
the UCI DNA Microarray Core Facility. Total RNA isolated
from separate cultures of serum-activated, serum-starved,
and purified, co-cultured fibroblasts was processed as rec-
ommended by Affymetrix Inc. [18]. The gene expression
results were quantified and analyzed using GCOS 1.1.1
software (Affymetrix Inc.) and/or ArrayAssist's gcRMA
(Iobion Informatics LLC, LaJolla, CA, USA) using default
values. Gene expression in a sample was considered to be
increased if the signal intensity was interpreted to be posi-
tive and at least fourfold higher (with P < 0.001) than the
baseline (defined as serum-starved fibroblasts in experi-
ment 1 or serum-activated fibroblasts cultured alone in
experiment 2).
In vivo metastasis study
In order to determine whether fibroblasts expressing α-
smooth muscle actin are in direct physical contact with
metastases of breast cancer cells, we immunostained 25
randomly selected specimens of metastatic human breast
cancer (ductal adenocarcinoma type) from the surgical
pathology and autopsy archives at UCI Medical Center
(Orange, CA, USA). These included four samples of well
differentiated ductal adenocarcinoma, nine samples of
moderately differentiated adenocarcinoma, and 12 sam-
ples of poorly differentiated carcinoma. Ten of the metas-
tases were to lymph nodes, six were to bone marrow, five
were to liver, two were to lung, one was to brain, and one
was to pleura. The age range of the patients was 42–69
years. The study set included eight samples with microme-
tastases, which we defined as fewer than 100 visible tumor
cells.
The slides were stained with prediluted murine monoclonal
antibody directed against α-smooth muscle actin (Ventana
Medical Systems, Phoenix, AZ, USA). Bound antibody was
detected using a biotin-streptavidin procedure employing
horseradish peroxidase as the detecting enzyme. Appropri-
ate positive and negative controls were included in each
staining run. In order to confirm that cells expressing
smooth muscle actin were myofibroblasts and not myoepi-
thelial cells, we also stained serial sections of the same tis-
sues with antibodies directed against CD10 and smooth
muscle myosin heavy chain. These markers are preferen-
tially expressed on myoepithelial cells [19] rather than
myofibroblasts.
Results
Microscopic appearance of co-cultured cells
When co-cultured with a monolayer of fibroblasts, the
UACC-812 cell line consistently produced colonies of
tumor cells that irregularly infiltrated the fibroblasts (Fig.
1b). Significantly, after just 14 days in co-culture the pri-
mary tumor cells derived directly from clinical specimens of
ductal carcinoma in situ (Fig. 1c) or invasive ductal carci-
noma (Fig. 1d) also produced multiple colonies in close
proximity to fibroblasts. The epithelial cells in these colo-
nies exhibited the usual cytologic features of malignancy,
including prominent nucleoli, a high nuclear:cyoplasmic
ratio, and marked cytologic atypia. Some of these colonies
consisted of nearly 100 tumor cells (Fig. 1c), suggesting a
doubling time of only 12 hours. It was also noteworthy that
the fibroblasts adjacent to the colonies of tumor cells invar-
iably expressed abundant α-smooth muscle actin (pink-
staining fibroblasts in Fig. 1c,d). When the UACC-812 cell
line was co-cultured on a monolayer of B16 melanoma
cells, clonogenic growth was nearly absent (Fig. 1e). More-
over, UACC-812 cells cultured in the absence of fibrob-
lasts survived only as individual cells or in very small
colonies, generally of fewer than eight cells (Fig. 1f). The
serum-activated fibroblasts in this model system uniformly
expressed syndecan-1 (Fig. 1g). There was no evidence of
overgrowth by fibroblasts during the course of the
experiment.
Clonogenic growth of breast cancer cells is promoted by 
direct contact with serum-activated fibroblasts
We performed co-culture experiments under a variety of
conditions that are summarized in Fig. 2. Tumor cells co-
cultured with serum-activated fibroblasts produced signifi-
cantly (P < 0.01) more colonies than did tumor cells cul-
tured in serum-containing medium without fibroblasts or
with fibroblasts in serum-free medium. Co-culture of the
tumor cells and fibroblasts in separate chambers of tran-
swells yielded low numbers of colonies, statistically identi-
cal to culture of tumor cells alone, as did co-culture on a
monolayer of B16 cells. Fibroblast conditioned medium
had no detectable effect on clonogenic growth of tumor
cells grown in the absence of fibroblasts (data not shown).
Serum-activated fibroblasts promote proliferation of 
breast cancer cells even at high densities of tumor cells
A graphical summary of the proliferation and apotosis data
from triplicate flow cytometry assays is presented in Fig. 3.
These data confirmed that high densities of breast cancer
cells co-cultured with fibroblasts had significantly higher
proliferative rates and lower apoptotic rates than did breast
cancer cells cultured in serum-supplemented medium with-
out fibroblasts.Available online http://breast-cancer-research.com/content/7/3/R274
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Clonogenic growth of primary tumor cells derived from 
clinical samples
The results of these experiments are shown in Table 1.
Each number in the table represents the total number of
colonies of tumor cells obtained when the epithelial cells
from one sample were cultured in the presence or absence
of serum-activated fibroblasts. Notably, all of the clinical
samples of ductal carcinoma in situ and invasive carcinoma
yielded substantially greater numbers of colonies when the
epithelial cells were co-cultured with fibroblasts. In addi-
tion, the average size of the colonies produced by carci-
noma cells co-cultured with fibroblasts (average 18 cells/
colony) appeared to be substantially greater than the colo-
nies produced by tumor cells cultured in the absence of
fibroblasts (average eight cells/colony). The sample of inva-
sive carcinoma that produced 33 colonies in the absence
of exogenous, serum-activated fibroblasts was notable for
the presence of numerous fibroblasts in the wells of the
negative control, thereby suggesting contamination of the
primary cancer cells by tumor-associated fibroblasts in that
sample. The other clinical samples had no visible contami-
nating fibroblasts in the wells that were seeded with tumor
cells alone. There was only minimal clonogenic growth of
cells obtained from benign breast tissues, and these cells
appeared cytologically benign.
Figure 2
Results of the co-culture assay Results of the co-culture assay. Each bar represents the mean and 
standard deviation of triplicate measurements. Tumor cells seeded on a 
monolayer of serum-activated fibroblasts produced the highest average 
number of colonies. There were significantly fewer colonies if fibrob-
lasts or serum were omitted. Co-culture with fibroblasts separated by 
permeable transwell inserts or on a monolayer of B16 cells yielded low 
numbers of colonies that were statistically indistinguishable from the 
control using tumor cells grown in serum-supplemented medium with-
out fibroblasts.
Figure 3
Results of flow cytometric measurements of proliferation and apoptosis Results of flow cytometric measurements of proliferation and apoptosis. 
There was a distinct peak of (b) breast cancer cells with a high prolifer-
ative rate compared with (a) breast cancer cells cultured without fibrob-
lasts. (c) Tumor cells grown on fibroblasts had a significantly higher 
proliferative rate and a lower apoptotic rate than did tumor cells cul-
tured alone.Breast Cancer Research    Vol 7 No 3    Samoszuk et al.
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Gene expression profile of serum-activated fibroblasts
Because the gene expression profile of tumor-associated
fibroblasts in situ has previously been described [20-22],
we used cDNA microarrays to compare the gene expres-
sion patterns of the serum-activated fibroblasts used in our
experiments with serum-starved fibroblasts, and to com-
pare serum-activated fibroblasts with serum-activated
fibroblasts that were co-cultured with tumor cells.
The results, shown in Table 2, confirm that serum-activated
fibroblasts differentially upregulated genes related to myofi-
broblast differentiation (LOXL2, PLOD2, PLAUR, TAGLN,
TPM2, MYL6, TFPI2) relative to serum-starved fibroblasts.
In addition, there was upregulated expression of two genes
that have previously been shown [20,22] to be highly asso-
ciated with tumor-associated fibroblasts in breast cancer
(CXCL12  and  CLIC4) and upregulation of the COX2
gene. Finally, we noted that serum-activated fibroblasts
also upregulated genes related to activation and function of
transforming growth factor (TGF)-β ( TGFB1,  LTBP2,
SMAD3). The gene expression profile of serum-activated
fibroblasts co-cultured with breast cancer cells was essen-
tially the same as the profile of serum-activated fibroblasts
cultured without tumor cells (data not shown).
α-Smooth muscle actin-positive fibroblasts are in direct 
contact with tumor cells in metastases of breast cancer
There was intense staining for α-smooth muscle actin in all
of the breast cancer metastases that we examined (Fig. 4).
Significantly, the fibroblasts in these tissues closely
enveloped the nests of tumor cells, even in the earliest
micrometastases to lymph nodes (Fig. 4c). Our immunos-
taining results demonstrated that virtually all of the tumor
cells were in direct contact or very close proximity to myofi-
broblasts, regardless of tumor grade or metastatic site.
There was little or no staining of these same tissues with
antibodies directed against CD10 or smooth muscle
Table 1
Numbers of colonies of breast cancer cells cultured with or without fibroblasts
Ductal carcinoma in situ (n = 3) Invasive carcinoma (n = 3)
With fibroblasts Without fibroblasts With fibroblasts Without fibroblasts
6210
1 0 130 33
65 12 21 0
Table 2
Myofibroblast-related genes that are differentially upregulated in fibroblasts activated by serum compared with serum-starved 
fibroblasts
Gene symbol Gene name Fold increase in signal intensity in serum-activated 
fibroblasts versus serum depleted fibroblasts (P < 0.001)
LOXL2 Lysyl oxidase-like 2 8.2
PLOD2 Procollagen-lysine, 2 oxoglutarate 5-dioxygenase 16
PLAUR Plasminogen activator urokinase receptor 5.3
TAGLN Transgelin 6.0
TPM2 Tropomysin 2 (beta) 4.6
MYL6 Myosin, light polypeptide 6, alkaline, smooth muscle 5.7
TFPI2 Tissue factor pathway inhibitor 2 4.8
SMAD3 Mothers against decapentaplegic homolog 3 (Drosophila)4 . 0
CXCL12 Chemokine (C-X-C motif) ligand 12 4.5
TGFB1 TGF-β, induced 26.5
LTBP2 Latent TGF-β binding protein 2 30.2
COX2 Cyclo-oxygenase-2 16.4
CLIC4 Chloride intracellular channel 4 32
TGF, transforming growth factor.Available online http://breast-cancer-research.com/content/7/3/R274
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myosin heavy chain, thereby indicating that the cells
expressing smooth muscle actin were myofibroblasts
rather than myoepithelial cells.
Discussion
We demonstrated that serum-activated human fibroblasts
significantly enhance the clonogenic growth of small num-
bers of primary breast cancer cells obtained directly from
clinical specimens. This effect requires direct physical con-
tact between tumor cells and the serum-activated fibrob-
lasts and cannot be replicated by fibroblast-conditioned
medium, co-culture in transwells, or co-culture on a monol-
ayer of another cell type (B16 cells). Moreover, we showed
that serum-activated fibroblasts exhibit many molecular
similarities to the fibroblasts that naturally infiltrate human
breast cancer, including expression of syndecan-1, α-
smooth muscle actin, and genes related to myofibroblast
differentiation and activation by TGF-β. Finally, we
demonstrated that fibroblasts expressing α-smooth muscle
actin are ubiquitously present in metastases of human
breast cancer and appear to be in close proximity or direct
physical contact with nearly all of the tumor cells. On aggre-
gate, these results provide further evidence of the essential
role played by serum-activated fibroblasts in promoting the
clonogenic growth of small numbers of breast cancer cells,
both in vitro and in vivo within metastases.
It has long been known that feeder cell layers of fibroblasts
can promote the growth of various cell lines in culture. Sur-
prisingly few studies, however, have directly related this
effect of feeder cells to the clonogenic growth of small
numbers of primary breast cancer cells in vitro. In one such
study investigators separated human breast cancer cell
lines from various types of fibroblasts with a microporous
membrane [7]. Under these conditions, tumor-associated
fibroblasts did not influence the proliferation of the two
breast cancer cell lines that were tested. This finding is
consistent with our observation that fibroblast conditioned
medium also does not promote the survival or clonogenic
growth of small numbers of breast cancer cells, and sug-
gests that a soluble growth factor or mediator is not
involved in the growth enhancement effect produced by
fibroblast feeder cell layers.
In a later study, Brooks and coworkers [8] demonstrated
that tumor-derived epithelial cells grew significantly better
on stroma produced by mammary fibroblasts than on bone
marrow stroma. Although it is generally difficult to culture
malignant epithelial cells from primary human breast can-
Figure 4
Immunohistochemical staining for α-smooth muscle actin in metastases of human breast cancer to (a) bone marrow, (b) liver, (c) lymph node, and  (d) pleura Immunohistochemical staining for α-smooth muscle actin in metastases of human breast cancer to (a) bone marrow, (b) liver, (c) lymph node, and 
(d) pleura. In all of the cases that we examined, there was extensive infiltration of the tumor metastases by myofibroblasts (brown stain). Note that the 
myofibroblasts appeared to be in direct contact with nearly all of the tumor cells in these sections. Even very early micrometastases (defined as fewer 
than 100 tumor cells) of well differentiated tumors to lymph nodes (panel c) and larger metastases of poorly differentiated tumors (panel d) were in 
very close proximity to myofibroblasts. Serial sections of the same tissues did not stain for CD10 or smooth muscle myosin heavy chain (not shown), 
thereby confirming that the cells are myofibroblasts rather than myoepithelial cells. Hematoxylin counter-stain was used.Breast Cancer Research    Vol 7 No 3    Samoszuk et al.
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cers, those investigators noted that a large proportion of
their samples (78%) successfully grew when co-cultured
with fibroblasts. They attributed this observation to their
source of tumor cells (metastases to lymph nodes), but an
equally plausible explanation is that the stromal cell layers
that they used in their experiments promoted the growth of
small numbers of tumor cells. Our study significantly
extends the findings of Brooks and coworkers [8] by dem-
onstrating that the ability of serum-activated fibroblasts to
enhance the clonogenic growth of small numbers of breast
cancer cells in vitro is not limited to cancer cells that have
metastasized to lymph nodes.
Although serum-activated fibroblasts promoted clonogenic
growth of breast cancer cells in our experimental model,
they did not appear to have a similar effect on benign breast
epithelial cells. Specifically, cells derived from benign
breast tissues yielded only small colonies of cells with
benign cytologic features as compared with cells derived
from malignant tissues. We attribute the slow growth of the
benign epithelial cells from the normal breast samples to
our use of a relatively un-enriched cell culture medium that
had been optimized for growth of normal fibroblasts rather
than epithelial cells. Benign mammary epithelial cells
normally require more specialized additives such as epider-
mal growth factor and bovine pituitary extract for optimal
growth. Hence, our clonogenic and cytologic findings
clearly suggest that serum-activated fibroblasts have a
more potent growth-promoting effect on malignant epithe-
lial cells than on benign breast cells.
Therefore, an important practical implication of our findings
is that the well known difficulty in growing primary human
breast cancer cells in vitro might be alleviated by simply co-
culturing the tumor cells with a monolayer of serum-acti-
vated, nonsenescent and nontransformed fibroblasts. In
this regard, it is interesting to note that virtually all current
methods for growing primary human breast cancer cells
rely on culturing purified epithelial cells that have been sep-
arated from the fibroblasts [10,11] in order to prevent
overgrowth by fibroblasts. Our data indicate that a monol-
ayer of serum-activated fibroblasts provides an excellent
substrate for growing small numbers of primary, human
breast cancer cells in vitro without overgrowth by fibrob-
lasts. In our model, the normal, nonsenescent fibroblasts
merely formed a monolayer and then appeared to stop
growing. We attribute this property to our use of normal,
nonsenescent fibroblasts that exhibited contact inhibition
of growth, which is characteristic of nontransformed cells.
Our observations also raise several important questions.
For example, how does serum activate fibroblasts? To what
extent do serum-activated fibroblasts in vitro resemble their
in vivo counterparts in human breast cancer? By what
mechanism(s) do serum-activated fibroblasts promote the
clonogenic growth of breast cancer cells?
Serum – the fluid component of clotted blood – contains
abundant coagulation-related substances, including
thrombin, TGF-β released from degranulating platelets, and
other serine proteases. The data from our gene expression
studies raise the intriguing possibility that TGF-β released
from degranulating platelets into clotting blood might be
involved in activating the fibroblasts. Specifically, we
observed high levels of expression of a chloride intracellular
channel gene, CLIC4, that is differentially expressed in
fibroblasts converted to myofibroblasts by TGF-β [20].
Morover, we observed that serum-activated fibroblasts
expressed high levels of genes encoding induced TGF-β
and latent TGF-β binding protein, which are expressed at
high levels in cultured human myofibroblasts [23]. Inas-
much as TGF-β has previously been shown to be a power-
ful activator of fibroblasts, our experimental observations
lead us to speculate that TGF-β released from degranulat-
ing platelets into serum could play a major role in the acti-
vation of tumor-associated fibroblasts by serum.
Experiments using DNA microarrays have demonstrated
that fibroblasts exhibit a temporal program of gene expres-
sion in response to serum exposure [24]. Notably, many
features of the transcriptional program appeared to be
related to the physiology of normal wound repair, including
the acquisition of a myofibroblast expression profile [24]. In
subsequent studies the gene expression signature of the
fibroblast serum response was also found in tumors and in
healing wounds [21], possibly because both processes
involve localized blood clotting and production of serum.
Our observations are consistent with and significantly
extend these previous findings. Specifically, we showed
that serum-activated fibroblasts express multiple genes
that are characteristic of tumor-associated myofibroblasts,
including the gene encoding CXC chemokine ligand-12,
which was recently shown to be highly overexpressed in
myofibroblasts associated with breast cancer [22]. In addi-
tion, we report the expression of genes related to TGF-β by
serum-activated fibroblasts. This finding is important
because a number of previous studies have demonstrated
that primary breast cancer fibroblasts secrete abundant
TGF-β [25,26]. Finally, our immunocytochemical studies
demonstrated that serum-activated fibroblasts uniformly
express high levels of syndecan-1, a proteoglycan that is
abundantly and specifically expressed by the stromal cells
and myofibroblasts that are present in the connective tissue
of human breast cancer [27,28]. Hence, we conclude that
the serum-activated fibroblasts used in our co-culture
model have many important similarities to the tumor-associ-
ated myofibroblasts that are naturally found in breast can-
cer [13].Available online http://breast-cancer-research.com/content/7/3/R274
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Interestingly, our gene expression data also suggest that
serum may play a more important role than contact with
tumor cells in activating fibroblasts because the gene
expression profile of serum-activated fibroblasts co-cul-
tured with tumor cells was essentially the same as the gene
expression profile of serum-activated fibroblasts cultured
alone. For example, the genes encoding cyclo-oxygenase-
2 and myofibroblast-related proteins were upregulated rel-
ative to serum-starved fibroblasts in serum activated fibrob-
lasts, regardless of whether the fibroblasts were co-
cultured with breast cancer cells. This finding is consistent
with the recent report of upregulation of the COX2 gene in
stromal fibroblasts co-cultured with pancreatic cells in a
transwell cell culture system [29]. In that report, however,
the authors attributed the COX2 upregulation to a soluble
factor produced by the pancreatic tumor cells. Our results
clearly indicate that serum alone can also upregulate COX2
gene expression.
In our study we did not directly explore the mechanism by
which serum-activated fibroblasts promote the clonogenic
growth of breast cancer cells. Elenbaas and Weinberg [1]
suggested that tumor-associated fibroblasts may promote
the growth of cancer cells through production of extracel-
lular matrix proteins and growth factors. A recent study con-
ducted by Palmieri and coworkers [30] indicated that
fibroblast growth factor 7 (keratinocyte growth factor)
secreted by breast fibroblasts is a potent paracrine growth
factor for human breast epithelial cells. The data from our
transwell experiments, however, suggest that soluble
growth factors by themselves are unlikely to promote clono-
genic growth of human breast cancer. Instead, direct phys-
ical contact between fibroblasts and tumor cells appears to
be necessary.
A reasonable mechanism to account for the necessity of
direct physical contact was recently proposed by Maeda
and coworkers [31], who showed that syndecan-1 expres-
sion by mouse embryonic fibroblasts promotes proliferation
of human breast cancer cell lines. Because the heparan
sulfate proteoglycans of syndecan-1 are known to facilitate
the assembly of signaling complexes between growth fac-
tors and their cognate receptors on breast cancer cells
[32,33], Maeda and coworkers concluded that stromal syn-
decan-1 on the surface of fibroblasts is a crucial factor reg-
ulating epithelial–stromal interactions in breast cancer. This
model would explain the observation that syndecan-1 is
required for Wnt-1-induced mammary tumorigenesis in
mice [33] and would also account for our experimental
findings.
Conclusion
Our observations establish serum-activated fibroblasts as a
critical promoter of clonogenic growth of small numbers of
human breast cancer cells in vitro and suggest that similar
activity might also be present in metastases of breast can-
cer in vivo. Further analysis of this interaction may lead to
the development of novel therapeutic targets.
Abbreviation
TGF = transforming growth factor.
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